Jocelyn Solis-Moreira

Feature Writer

B.Sc. Integrative Neuroscience, M.Sc. Psychology

Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood. She is adept at translating and summarizing complex study findings in all medical fields with a particular interest in neurodegenerative diseases, cancer research, infectious diseases, and public health. As a freelance writer, her work spans from news articles and feature articles to evergreen explainers across many publications. Her overall goal is to make science accessible for all.

Articles from Jocelyn

COVID-19 severity is correlated with T cell receptor repertoire signatures

In a new study published in the bioRxiv* preprint server, researchers found that specific TCR sequences predicted the severity of coronavirus disease 2019 (COVID-19) infection. Additionally, there was evidence of increased CDR3 sequences and changes in k-mer motifs for patients with severe illness.

6 Dec 2021

Simple quantitative framework to understand the pathogenesis of severe COVID-19

Researchers from Los Alamos National Laboratory in the United States developed a model to explain why severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections induce high inflammatory levels.

6 Dec 2021

Omicron variant increases risk of SARS-CoV-2 reinfection

New surveillance data from South Africa published in the medRxiv* preprint server suggests that the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omnicron variant has the potential to escape naturally-acquired immunity. The research indicates people who previously recovered from a coronavirus disease 2019 (COVID-19) are at risk for reinfection with the Omicron variant. The results show that the risk of reinfection is greater with the Omicron variant versus Delta and Beta.

6 Dec 2021

The link between cytokine storms and cardiovascular problems in COVID-19 patients

New findings may help doctors choose effective COVID-19 treatment regimens for patients with heart complications.

6 Dec 2021

A case of post-vaccination MIS in an adult without prior SARS-CoV-2 infection

A new case study on the report of multisystem inflammatory syndrome (MISC) in a 22-year-old woman in South Korea after vaccination.

5 Dec 2021

CDC study finds Pfizer-BioNTech COVID vaccine provides high protection against hospitalization in adolescents

New research from the Centers for Disease Control & Prevention (CDC) suggest vaccines are highly protective against severe acute respiratory coronavirus 2 (SARS-CoV-2). Two doses of the Pfizer-BioNTech vaccine showed a 93% effectiveness against hospitalization. The findings add to a previous clinical trial that found vaccinated adolescents with 100% protection against SARS-CoV-2 infections.

23 Nov 2021

Effectiveness of public health measures in reducing COVID-19 incidence

A new review suggests public health measures such as mask-wearing, universal lockdowns, and temporary shutdowns of businesses and schools helped prevent further SARS-CoV-2 transmission.

23 Nov 2021

Does SARS-CoV-2 infection contribute to adrenal gland dysfunction?

New research suggests that SARS-CoV-2 infection can directly target and cause cellular damage to the adrenal glands.

23 Nov 2021

CoronaVac vaccine booster strengthens protection against SARS-CoV-2

In a recent study published on the preprint medRxiv* server, an international team of scientists tested CoronaVac as a booster shot and measured its effects on immunity. Their findings showed increases in neutralizing antibodies and T cell response.

21 Nov 2021

Scientists discover several factors influencing waning immunity with the Pfizer COVID Vaccine

New research from Japan found several risk factors associated with greater waning immunity after vaccination. Old age and smoking were amongst those with some of the lowest antibody titers. Women more than men were also more likely to experience a rapid decline in antibody levels 3 to 6 months after receiving their second Pfizer-BioNTech dose.

21 Nov 2021